TY - JOUR
T1 - Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion
AU - Impellizzeri, Daniela
AU - Bruschetta, Giuseppe
AU - Ahmad, Akbar
AU - Crupi, Rosalia
AU - Siracusa, Rosalba
AU - Di Paola, Rosanna
AU - Paterniti, Irene
AU - Prosdocimi, Marco
AU - Esposito, Emanuela
AU - Cuzzocrea, Salvatore
N1 - Publisher Copyright:
© 2015 Elsevier B.V. All rights reserved.
PY - 2015/6/3
Y1 - 2015/6/3
N2 - The aim of this study was to investigate the efficacy of PEA+silymarin as a combination treatment in a mouse model of renal I/R and to verify whether PEA+silymarin could exert more potent effects compared to the single substances even if administered at lower doses. Mice were subjected to bilateral renal artery occlusion (30 min) and reperfusion (6 h) and received intraperitoneally silymarin (100, 30 and 10 mg/kg) or PEA (1 mg/kg) or PEA (1 mg/kg)+silymarin (10 mg/kg) 15 min before release of clamps. Specific indicators of renal dysfunction, tubular injury, myeloperoxidase activity and malondialdehyde levels were measured. The nuclear factor κB pathway and apoptotic mechanisms were also investigated. The treatment with silymarin reduced kidney dysfunction, histological damage, neutrophil infiltration and oxidative stress in a dose dependent manner. Furthermore, PEA+silymarin showed a significant potentiated effect. Therefore, NF-κB and apoptosis pathways were also significantly inhibited. Our results clearly demonstrate that PEA+silymarin treatment attenuated the degree of renal inflammation.
AB - The aim of this study was to investigate the efficacy of PEA+silymarin as a combination treatment in a mouse model of renal I/R and to verify whether PEA+silymarin could exert more potent effects compared to the single substances even if administered at lower doses. Mice were subjected to bilateral renal artery occlusion (30 min) and reperfusion (6 h) and received intraperitoneally silymarin (100, 30 and 10 mg/kg) or PEA (1 mg/kg) or PEA (1 mg/kg)+silymarin (10 mg/kg) 15 min before release of clamps. Specific indicators of renal dysfunction, tubular injury, myeloperoxidase activity and malondialdehyde levels were measured. The nuclear factor κB pathway and apoptotic mechanisms were also investigated. The treatment with silymarin reduced kidney dysfunction, histological damage, neutrophil infiltration and oxidative stress in a dose dependent manner. Furthermore, PEA+silymarin showed a significant potentiated effect. Therefore, NF-κB and apoptosis pathways were also significantly inhibited. Our results clearly demonstrate that PEA+silymarin treatment attenuated the degree of renal inflammation.
KW - Apoptosis
KW - Cytokines
KW - Inflammation
KW - Oxidative stress
KW - Renal disease
UR - http://www.scopus.com/inward/record.url?scp=84930686012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930686012&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2015.05.010
DO - 10.1016/j.ejphar.2015.05.010
M3 - Article
C2 - 25981305
AN - SCOPUS:84930686012
SN - 0014-2999
VL - 762
SP - 136
EP - 149
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -